Given the facts that GSK-470 failed to inhibit phospho-mTOR at Ser2448 and its downstream phospho-AKT (Ser473), which was demonstrated in this study, and that dual mTORC1/C2 inhibitors is much more active than mTORC1 inhibition alone in myeloma cells [27], we examined whether PP242, a non-rapalog agent that targets simultaneously mTORC1 and mTORC2 [28], enhances GSK-470-mediated cell death. Here, AKT1 is linked to plasma cell myeloma.